CEBPA Mutation Detection
2004247
Ordering Recommendation
Initial test for prognostication of CN-AML.
Mnemonic
CEBPA MUT
Methodology
Polymerase Chain Reaction/Sequencing
Performed
DNA isolation: Sun-Sat
Assay:
Mon, Wed, Fri
Reported
12-14 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA) OR bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL) OR 3 mL bone marrow (Min: 1 mL).  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
81403
Components
Component Test Code*Component Chart Name
2004249CEBPA Mutation Detection Results
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • CCAAT Enhancer Binding Protein Alpha
  • CEBP Alpha
  • CEBPA Mutation Analysis